BIP Winter 2025

Industry Innovation

TrumpRx.gov introduces a new twist in drug pricing The administration’s direct-to-consumer platform aims to lower prescription costs by bypassing PBMs, but its impact on insured Americans remains uncertain. By Craig Hasday

President Donald Trump’s announcement of a landmark deal with pharmaceutical giant Pfizer and AstraZeneca (with potentially more manufacturers to follow) revolving around the new federal website, TrumpRx. gov, has introduced a major, and highly political, shift into the prescription drug landscape. The administration has made clear its intention to lower exorbitant U.S. drug prices and align them with those of other developed countries (a concept known as most-favored-nation pricing). The core premise of the deal, as framed by the administration and Pfizer CEO Albert Bourla, is to end the “unfair situation” where American consumers effectively subsidize global drug research and development. Under the agreement, Pfizer has committed to pricing new drugs in the U.S. at parity with those same drugs in developed nations. Furthermore, the company will offer discounted prices on a range of its current medications through the upcoming federal platform. The mechanism The TrumpRx.gov website, slated to launch in 2026, will act as a search portal,

Set to launch in 2026, Trump Rx.gov will act as a search portal for existing direct-to consumer drug fulfillment.

redirecting consumers to the pharmaceutical manufacturer’s existing direct-to-consumer (DTC) channels for fulfillment. Pfizer, the first major drugmaker to sign on, has promised discounts averaging about 50% lower than current

prices for its participating drugs, with some savings reaching up to 85%. This model aims to bypass middlemen like pharmacy benefit managers (PBMs), a strategy that mirrors the approach of other private initiatives like Mark

erdikocak / iStock

16 bip magazine Winter 2025